Grace Therapeutics, Inc.
GRCE
$2.27
-$0.03-1.30%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 30.35% | 1.33% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 22.91% | -3.16% | |||
| Operating Income | -22.91% | 3.16% | |||
| Income Before Tax | -24.32% | -146.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 49.11% | -146.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 49.11% | -146.80% | |||
| EBIT | -22.91% | 3.16% | |||
| EBITDA | -22.98% | 3.28% | |||
| EPS Basic | 50.04% | -132.09% | |||
| Normalized Basic EPS | -22.01% | -132.07% | |||
| EPS Diluted | 50.04% | -132.09% | |||
| Normalized Diluted EPS | -22.01% | -132.07% | |||
| Average Basic Shares Outstanding | 1.91% | 6.34% | |||
| Average Diluted Shares Outstanding | 1.91% | 6.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||